Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Project leader/senior scientist at UniBern.
2 years in pharma industry.
8 years of research activity on the ECS
Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.
Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022
We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, collaborators, and investors.
https://www.linkedin.com/feed/update/urn:li:activity:6973356870988128256
https://twitter.com/venturelab_ch/status/1567797207071334400
Synendos Therapeutics has been awarded with the Innosuisse Certificate Synendos has been awarded the Innosuisse certificate by Innosuisse Innovation Council. The Innosuisse certificate reflects remark
In a last newsletter edition from NCCR Transcure, we can look behind the scenes of our technology transfer success story.
Synendos Therapeutics is thrilled to announce the formation of the Scientific Advisory Board.